Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Corcept Therapeutics (NQ: CORT ) 34.26 +0.38 (+1.12%) Streaming Delayed Price Updated: 11:43 AM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 229,043 Open 34.30 Bid (Size) 34.20 (4) Ask (Size) 34.27 (1) Prev. Close 33.88 Today's Range 33.99 - 34.48 52wk Range 20.87 - 35.22 Shares Outstanding 115,926,629 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation. July 15, 2024 CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating. Via Chartmill Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. July 15, 2024 For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. Via Chartmill Performance YTD +41.80% +41.80% 1 Month +14.05% +14.05% 3 Month +53.63% +53.63% 6 Month +45.42% +45.42% 1 Year +41.05% +41.05% More News Read More 7 Biotech Stocks to Boost Your Portfolio to Peak Health June 26, 2024 Via InvestorPlace Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 June 26, 2024 Via InvestorPlace Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire 6 Analysts Have This To Say About Corcept Therapeutics June 17, 2024 Via Benzinga NASDAQ:CORT is not too expensive for the growth it is showing. May 31, 2024 Via Chartmill While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. June 24, 2024 Via Chartmill Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know June 14, 2024 Via Benzinga Topics Lawsuit Exposures Financial Legal Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) May 29, 2024 Via Benzinga Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. May 09, 2024 Via Chartmill The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts May 02, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session June 03, 2024 Via Benzinga Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 03, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday May 28, 2024 Via Benzinga Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 28, 2024 Via Benzinga Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday? May 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 28, 2024 Via Benzinga Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. May 10, 2024 Via Chartmill 10 Health Care Stocks With Whale Alerts In Today's Session May 09, 2024 Via Benzinga CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 Via InvestorPlace Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 4 CATALYST Trial April 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
